Cargando…
The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry
INTRODUCTION: Omalizumab is indicated for the treatment of severe allergic asthma (SAA) and chronic spontaneous urticaria, although a number of studies have confirmed the effectiveness of this therapy also for other IgE-mediated diseases. AIM: To assess the impact of anti-IgE therapy on SAA and como...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232552/ https://www.ncbi.nlm.nih.gov/pubmed/30429711 http://dx.doi.org/10.5114/ada.2018.77243 |
_version_ | 1783370413107052544 |
---|---|
author | Hutyrová, Beáta Bystroň, Jaromír |
author_facet | Hutyrová, Beáta Bystroň, Jaromír |
author_sort | Hutyrová, Beáta |
collection | PubMed |
description | INTRODUCTION: Omalizumab is indicated for the treatment of severe allergic asthma (SAA) and chronic spontaneous urticaria, although a number of studies have confirmed the effectiveness of this therapy also for other IgE-mediated diseases. AIM: To assess the impact of anti-IgE therapy on SAA and comorbid IgE-mediated allergic diseases in patients treated with omalizumab for SAA enrolled in the CAR (Czech Anti-IgE Registry). MATERIAL AND METHODS: Three hundred and ten patients with SAA treated with omalizumab were enrolled in the CAR. Two hundred and twenty-nine individuals were evaluated after 12 months of omalizumab treatment for asthma control test (ACT), examination of fractional exhaled nitric oxide (FENO), forced expiratory volume in 1 s (FEV(1)), the use of systemic corticosteroids, side effects of treatment and clinical effect of omalizumab on allergic comorbidities (allergic rhinitis, chronic urticaria, atopic dermatitis and food allergy). RESULTS: After 12 months of treatment with omalizumab, patients experienced a significant improvement of ACT and FEV(1), reduction of FENO, use of systemic corticosteroids for asthma exacerbations and dose of maintenance oral corticosteroid therapy. The positive effect of treatment with omalizumab was observed in 82.2% of patients with allergic rhinitis, in 85.7% of patients with chronic urticaria, in 82.1% of patients with atopic dermatitis, and in 67.3% of patients with food allergy. CONCLUSIONS: In the CAR registry, patients with SAA treated with omalizumab showed a significant positive effect of anti-IgE therapy not only on the asthma control, but also on allergic comorbidities. |
format | Online Article Text |
id | pubmed-6232552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-62325522018-11-14 The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry Hutyrová, Beáta Bystroň, Jaromír Postepy Dermatol Alergol Original Paper INTRODUCTION: Omalizumab is indicated for the treatment of severe allergic asthma (SAA) and chronic spontaneous urticaria, although a number of studies have confirmed the effectiveness of this therapy also for other IgE-mediated diseases. AIM: To assess the impact of anti-IgE therapy on SAA and comorbid IgE-mediated allergic diseases in patients treated with omalizumab for SAA enrolled in the CAR (Czech Anti-IgE Registry). MATERIAL AND METHODS: Three hundred and ten patients with SAA treated with omalizumab were enrolled in the CAR. Two hundred and twenty-nine individuals were evaluated after 12 months of omalizumab treatment for asthma control test (ACT), examination of fractional exhaled nitric oxide (FENO), forced expiratory volume in 1 s (FEV(1)), the use of systemic corticosteroids, side effects of treatment and clinical effect of omalizumab on allergic comorbidities (allergic rhinitis, chronic urticaria, atopic dermatitis and food allergy). RESULTS: After 12 months of treatment with omalizumab, patients experienced a significant improvement of ACT and FEV(1), reduction of FENO, use of systemic corticosteroids for asthma exacerbations and dose of maintenance oral corticosteroid therapy. The positive effect of treatment with omalizumab was observed in 82.2% of patients with allergic rhinitis, in 85.7% of patients with chronic urticaria, in 82.1% of patients with atopic dermatitis, and in 67.3% of patients with food allergy. CONCLUSIONS: In the CAR registry, patients with SAA treated with omalizumab showed a significant positive effect of anti-IgE therapy not only on the asthma control, but also on allergic comorbidities. Termedia Publishing House 2018-07-19 2018-10 /pmc/articles/PMC6232552/ /pubmed/30429711 http://dx.doi.org/10.5114/ada.2018.77243 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Hutyrová, Beáta Bystroň, Jaromír The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title | The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title_full | The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title_fullStr | The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title_full_unstemmed | The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title_short | The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry |
title_sort | effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the czech anti-ige registry |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232552/ https://www.ncbi.nlm.nih.gov/pubmed/30429711 http://dx.doi.org/10.5114/ada.2018.77243 |
work_keys_str_mv | AT hutyrovabeata theeffectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry AT bystronjaromir theeffectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry AT theeffectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry AT hutyrovabeata effectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry AT bystronjaromir effectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry AT effectofomalizumabtreatmentonsevereallergicasthmaandallergiccomorbiditiesreallifeexperiencefromtheczechantiigeregistry |